LEVOXINE (Sun Pharma ANZ Pty Ltd)

Product name

LEVOXINE

Date registered

29 July 2021

Approval time

173 (255 working days)

Active ingredients

levothyroxine sodium

Registration type

New generic medicine

Indication

LEVOXINE (tablet) is indicated for the management of demonstrated thyroid hormone deficiency.

LEVOXINE is also used to suppress thyrotropin (TSH) for the management of TSH-responsive tumours of the thyroid.

Registration process

First generic

First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine